Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307574 | 0.73 | PIK3CA (0.34) | PIK3CA | |
| SCHEMBL23887394 | 0.73 | PIK3CA (0.34) | PIK3CA | |
| SCHEMBL25679548 | 0.73 | PIK3CA (0.34) | PIK3CA | |
| SCHEMBL31035274 | 0.72 | PIK3CA (0.36) | PIK3CACDK2KDM4EHSD17B10 | |
| SCHEMBL31035774 | 0.71 | AKT1 (0.37) | PIK3CACDK2KDM4EHSD17B10 | |
| SCHEMBL31035348 | 0.69 | ALDH1A1 (0.32) | KDM4EHSD17B10 | |
| SCHEMBL30889677 | 0.68 | PIK3CA (0.38) | PIK3CA | |
| SCHEMBL30064040 | 0.68 | PIK3CA (0.39) | PIK3CACDK2 | |
| SCHEMBL23887051 | 0.68 | PIK3CA (0.39) | PIK3CACDK2 | |
| SCHEMBL31035499 | 0.68 | PIK3CA (0.38) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126851-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES ASSOCIATED WITH P13K MODULATION | Petra Pharma Corporation (US) | 2023-02-08 | — | — | EP | disclosed |